Theratechnologies Company Overview
About Theratechnologies
Theratechnologies (TSX:TH), (NASDAQ:THTX), a biopharmaceutical company, focuses on innovative therapies for metabolic disorders and conditions, notably in areas related to HIV. It actively engages in the research, development, and commercialization of products aimed at improving the quality of life for people dealing with metabolic diseases. Among its notable projects are treatments for complications associated with HIV, including excess abdominal fat in HIV-infected patients on antiretroviral therapy. A key objective for Theratechnologies is to advance their pipeline of products through clinical trials, ensuring they meet rigorous safety and efficacy standards. Their pursuit of medical breakthroughs is aimed at addressing unmet medical needs, making a significant impact on patient care in their target markets.
Snapshot
Operations
Products and/or services of Theratechnologies
- EGRIFTA and EGRIFTA SV, treatments aimed at reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
- TESAMORELIN, a growth hormone-releasing factor analog for the treatment of lipodystrophy.
- F8 Formulation technology, designed to improve the delivery and effectiveness of existing medications.
- TROGARZO, an antiretroviral therapy for multidrug-resistant HIV-1 infection.
- TH1902, a targeted therapy for sortilin-positive cancers in the preclinical development stage.
- Research and development efforts focused on metabolic disorders and HIV, exploring innovative solutions to address unmet medical needs.
Theratechnologies executive team
- Mr. Paul LévesquePresident, CEO & Director
- Mr. Philippe Dubuc M.B.A., MBASenior VP & CFO
- Mr. Jocelyn Lafond L.L.M., LL.B.General Counsel & Corporate Secretary
- Dr. Christian Marsolais Ph.D.Senior VP & Chief Medical Officer
- Mr. John LeasureGlobal Commercial Officer
- Hon. Andre Dupras M.Sc.Vice President of Human Resources
- Mr. Julie SchneidermanSenior Director, Communications & Corporate Affairs